企业邮箱
MEBO US Initiated FDA Development Policy Conference in US
2014年-12月-24日
来源：MEBO
MEBO US Initiated FDA Development Policy Conference in US
October 14th, 2014, MEBO FDA Development Conference was held in Arizona of US. Directed by Steven Kishter, MD, DDS, the counselor of US President Science Policy, the leader of Guide about Plant Drugs and the leader of former Plant Drug Medicine, the conference worked out its general blueprint for future FDA development. Prof. Xu Rongxiang, the inventor of Human Body Regeneration Science and Board Director of MEBO delivered theme report about science and clinical technical standards. KEVIN FOSTER,MD,MBA, delivered general report about future organization and work, Mr. Xu Peng, MEBO INTERNATIONAL CEO, delivered report about progressing organizations. JIAYAO ERIC WANG MD, CEO of SKINGENIX, and director of SKINGENIX Clinical Department made report about CMC and clinical test. The conference started from FDA development and worked out the route map for human kind to benefit from organ regeneration. This is also to implement the policy of the US President to develop damaged organ regeneration medicine. We have unprecedented advantages in clinical application with mixed elements of plant drugs approved by FDA.
The conference determined the development policy of FDA drugs based on organ regeneration science and stipulated the development decision in details, e.g. with third phase clinical application of diabetic ulcer and the burns as the start to initiate FDA Drug Plan based on damaged organ regeneration science. At the same time, the plan related to FDA drugs development based on damaged internal organ will also be started. The FDA medicine development conference will be held on November 9th of 2014 in Washington D.C., thus unfolding a new page for human beings with regard to the first generation of drugs for damaged organ.
Photo of All Decision Makers